Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock Award Plans (Tables)

Stock Award Plans (Tables)

6 Months Ended

Jun. 30, 2013

Schedule of stock-based compensation expense related to all of the entity's stock-based awards

Total stock-based compensation expense related to all of our stock-based awards that we recognized was as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Research and development	$	1,002	$	1,636	$	2,025	$	3,348
General and administrative	745		1,375		1,515		2,761
Total stock-based compensation expense	$	1,747	$	3,011	$	3,540	$	6,109

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans

	Equity Incentive Plans				Equity Incentive Plans
	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Risk-free interest rate	0.9	%	0.8	%	0.8	%	0.9	%
Expected term (in years)	6.0		5.8		5.5		5.5
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	83.8	%	80.1	%	73.9	%	81.6	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan

	Employee Stock Purchase Plan
	Six Months Ended
	June 30,
	2013		2012
Risk-free interest rate	0.2	%	0.1	%
Expected term (in years)	1.4		0.5
Dividend yield	0.0	%	0.0	%
Expected volatility	58.0	%	49.7	%

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details